Portfolio swung to NZ$32.6m loss as NTA fell 26% to 64 cents

Investment total return swung to in FY22 from +NZ$57.2m in FY21. Annolyse's historical baseline classifies this as an unprecedented low against a 4-period mean of +NZ$36.6m (range +NZ$12.5m to +NZ$57.2m), and it is the lead finding because it drove almost every other negative movement in the result.

NTA per share fell from $0.87 to $0.64 (-26.4%) and net assets attributable declined 8.1% to NZ$170.7m, the lowest in the supplied 4-period history (baseline mean NZ$210.4m). Reported NPAT inverted to -NZ$34.6m from +NZ$52.3m (-166.2%), and ROE swung to -19.4% versus +25.4% prior — also classified as an unprecedented low.

Underlying investment income (dividend and interest receipts, excluding fair-value movements) was NZ$3.8m, up 13.6% from NZ$3.3m, sitting at the lower edge of the historical range. The final dividend stepped down to 1.36 cps from 1.69 cps, but full-year distributions paid rose to NZ$11.0m from NZ$8.1m.

The fair-value-driven portfolio loss of NZ$32.6m is the dominant figure and pulled NAV per share down 26.4% in a single year. For a listed investment company, this is the result that matters most because shareholder value is anchored to NTA, not to the income line.

Distribution coverage from income weakened further. Investment income of NZ$3.8m covered only 34.4% of distributions paid (NZ$11.0m), down from 41.1% in FY21. The remaining ~66% was funded from capital, which is normal for this vehicle's distribution policy but becomes more material when NAV is contracting — the same dollar distribution now represents a larger share of a smaller asset base.

Benchmark context implies severe relative underperformance. The benchmark total return of 70.0% is classified as within the historical range (4-period mean 59.5%), so this was not a market in which broad equity benchmarks were down. BRM's portfolio losing NZ$32.6m against that backdrop suggests stock-specific, not market-wide, drivers — consistent with the named concentrated holdings (CSL, Carsales, Wisetech, AUB).

No stated targets are supplied. The interim shape, however, is informative: HY22 delivered +NZ$14.9m NPAT, which implies a second-half NPAT of to reach the -NZ$34.6m full-year figure. That means the deterioration accelerated meaningfully into the second half, consistent with the rate-driven re-rating of growth equities the commentary alludes to. Without forward NAV guidance, the release does not support a view on whether the H2 trajectory has stabilised; it only confirms the H2 was materially worse than the H1.

The NZ$34.6m loss is dominated by unrealised fair-value movements, which are mark-to-market and reversible if holdings re-rate — they are not a cash outflow and do not reflect impaired earnings power of the portfolio companies themselves.

That said, the result is genuinely lower quality in three respects. NAV per share has fallen 26.4% and is real for any shareholder transacting today. Distribution coverage from investment income deteriorated to 34.4%, so the gap between income and distributions widened. And ROE at -19.4% — even acknowledging it is fair-value-driven — is the weakest in the supplied 4-period baseline, which sets a higher bar for FY23 just to return to a long-run mean. Operating cash flow movements at this entity reflect investment timing rather than working capital, so standard cash-conversion framing is not applicable.

This briefing cannot assess post-balance-date NAV recovery, the realised/unrealised composition of the portfolio loss, or whether the holdings have been repositioned since year-end.